ACR Appropriateness Criteria® Resectable Rectal Cancer

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Jones III, William E ^a   Thomas Jr, Charles R ^b   Herman, Joseph M ^c   Abdel Wahab, May ^d   Azad, Nilofer ^c   Blackstock, William ^e   Das, Prajnan ^f   Goodman, Karyn A ^g   Hong, Theodore S ^h   Jabbour, Salma K ⁱ   Konski, Andre A ^j   Koong, Albert C ^k   Rodriguez Bigas, Miguel ^f   Small Jr, William ^l   Zook, Jennifer ^m   Suh, W W ⁿ  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e WAKE FOREST UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^j WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^l NORTHWESTERN UNIVERSITY   (United States)

^m INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ Cancer Center of Santa Barbara   (United States)

more..

Author keywords

Appropriateness criteria; Chemoradiotherapy; Chemotherapy; Radiotherapy; Rectal cancer

Indexed keywords

CAPECITABINE; FLUOROURACIL; OXALIPLATIN;

BODY POSTURE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRACTICE GUIDELINE; RADIATION DOSE; RECTUM CANCER; REVIEW; SUPINE POSITION; TREATMENT RESPONSE; TUMOR LOCALIZATION;

ADULT; AGED; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; EUROPE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MEDICAL ONCOLOGY; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECTAL NEOPLASMS; TREATMENT OUTCOME; UNITED STATES;

EID: 84866514921     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-161     Document Type: Review

References (48)

1. National Cancer Institute Comprehensive Cancer Information http://www.cancer.gov/cancertopics/types/colon-and-rectal Accessed 5 January 2012, National Cancer Institute.
2. Rich T, Gunderson LL, Lew R, Galdibini JJ, Cohen AM, Donaldson G. Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer 1983, 52(7):1317-1329. 10.1002/1097-0142(19831001)52:7<1317::AID-CNCR2820520731>3.0.CO;2-6, 6192900.
3. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351(17):1731-1740. 10.1056/NEJMoa040694, 15496622.
4. Bernstein TE, Endreseth BH, Romundstad P, Wibe A. Circumferential resection margin as a prognostic factor in rectal cancer. Br J Surg 2009, 96(11):1348-1357. 10.1002/bjs.6739, 19847867.
5. Tilney HS, Rasheed S, Northover JM, Tekkis PP. The influence of circumferential resection margins on long-term outcomes following rectal cancer surgery. Dis Colon Rectum 2009, 52(10):1723-1729. 10.1007/DCR.0b013e3181b54fbd, 19966604.
6. Gosens MJ, Klaassen RA, Tan-Go I, et al. Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal carcinoma. Clin Cancer Res 2007, 13(22 Pt 1):6617-6623.
7. Quirke P, Steele R, Monson J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009, 373(9666):821-828. 10.1016/S0140-6736(09)60485-2, 2668948, 19269520.
8. Mohiuddin M, Winter K, Mitchell E, et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 2006, 24(4):650-655. 10.1200/JCO.2005.03.6095, 16446336.
9. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991, 324(11):709-715. 10.1056/NEJM199103143241101, 1997835.
10. Thomas PR, Lindblad AS. Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience. Radiother Oncol 1988, 13(4):245-252. 10.1016/0167-8140(88)90219-8, 3064191.
11. Tveit KM, Guldvog I, Hagen S, et al. Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group. Br J Surg 1997, 84(8):1130-1135. 10.1002/bjs.1800840827, 9278661.
12. Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988, 80(1):21-29. 10.1093/jnci/80.1.21, 3276900.
13. Wolmark N, Wieand HS, Hyams DM, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 2000, 92(5):388-396. 10.1093/jnci/92.5.388, 10699069.
14. Smalley SR, Benedetti JK, Williamson SK, et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 2006, 24(22):3542-3547. 10.1200/JCO.2005.04.9544, 16877719.
15. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994, 331(8):502-507. 10.1056/NEJM199408253310803, 8041415.
16. Tepper JE, O'Connell MJ, Petroni GR, et al. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol 1997, 15(5):2030-2039.
17. Lee JH, Ahn JH, Bahng H, et al. Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report. J Clin Oncol 2002, 20(7):1751-1758. 10.1200/JCO.2002.07.037, 11919231.
18. Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005, 23(24):5644-5650. 10.1200/JCO.2005.08.144, 16110023.
19. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997, 336(14):980-987.
20. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 2005, 23(34):8697-8705. 10.1200/JCO.2005.02.9017, 16314629.
21. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Late gastrointestinal disorders after rectal cancer surgery with and without preoperative radiation therapy. Br J Surg 2008, 95(2):206-213.
22. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345(9):638-646. 10.1056/NEJMoa010580, 11547717.
23. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009, 373(9666):811-820. 10.1016/S0140-6736(09)60484-0, 2668947, 19269519.
24. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006, 355(11):1114-1123. 10.1056/NEJMoa060829, 16971718.
25. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006, 24(28):4620-4625. 10.1200/JCO.2006.06.7629, 17008704.
26. Roh MS, Colangelo LH, O'Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009, 27(31):5124-5130. 10.1200/JCO.2009.22.0467, 2773471, 19770376.
27. Roh MS, Colangelo L, Wieand S, et al. Response to preoperative multimodality therapy predicts survival in patients with carcinoma of the rectum. ASCO Meeting Abstracts 2004, 22(14):3505.
28. Kim TH, Chie EK, Kim DY, et al. Comparison of the belly board device method and the distended bladder method for reducing irradiated small bowel volumes in preoperative radiotherapy of rectal cancer patients. Int J Radiat Oncol Biol Phys 2005, 62(3):769-775. 10.1016/j.ijrobp.2004.11.015, 15936558.
29. Siddiqui F, Shi C, Papanikolaou N, Fuss M. Image-guidance protocol comparison: supine and prone set-up accuracy for pelvic radiation therapy. Acta Oncol 2008, 47(7):1344-1350. 10.1080/02841860802304564, 18663650.
30. Drzymala M, Hawkins MA, Henrys AJ, Bedford J, Norman A, Tait DM. The effect of treatment position, prone or supine, on dose-volume histograms for pelvic radiotherapy in patients with rectal cancer. Br J Radiol 2009, 82(976):321-327.
31. Tulchinsky H, Shmueli E, Figer A, Klausner JM, Rabau M. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol 2008, 15(10):2661-2667. 10.1245/s10434-008-9892-3, 18389322.
32. Habr-Gama A, Perez RO, Proscurshim I, et al. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome?. Int J Radiat Oncol Biol Phys 2008, 71(4):1181-1188. 10.1016/j.ijrobp.2007.11.035, 18234443.
33. Roh MS, Yothers GA, O'Connell MJ, et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. ASCO Meeting Abstracts 2011, 29(15):3503.
34. Hofheinz R, Wenz FK, Post S, et al. Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial. ASCO Meeting Abstracts 2011, 29(15):3504.
35. Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010, 28(10):1638-1644. 10.1200/JCO.2009.25.8376, 20194850.
36. Valentini V, Coco C, Minsky BD, et al. Randomized, multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: raltitrexed + oxaliplatin + radiotherapy versus cisplatin + 5-fluorouracil + radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70(2):403-412. 10.1016/j.ijrobp.2007.06.025, 17919844.
37. Kiran RP, Nisar PJ, Pelley RJ, Fazio VW, Lavery IC. Role of routine adjuvant chemotherapy after neoadjuvant chemoradiotherapy and resection in low-risk patients with rectal cancer. ASCO Meeting Abstracts 2011, 29(15):e14032.
38. Garofalo M, Moughan J, Hong T, et al. RTOG 0822: A Phase II Study of Preoperative (PREOP) Chemoradiotherapy (CRT) Utilizing IMRT in Combination with Capecitabine (C) and Oxaliplatin (O) for Patients with Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys 2011, 81(2):S3-S4.
39. Samuelian JM, Callister MD, Ashman JB, Young-Fadok TM, Borad MJ, Gunderson LL. Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2012, 82(5):1981-1987. 10.1016/j.ijrobp.2011.01.051, 21477938.
40. Fuller CD, Nijkamp J, Duppen JC, et al. Prospective randomized double-blind pilot study of site-specific consensus atlas implementation for rectal cancer target volume delineation in the cooperative group setting. Int J Radiat Oncol Biol Phys 2011, 79(2):481-489. 10.1016/j.ijrobp.2009.11.012, 2929319, 20400244.
41. Fuller CD, Nijkamp J, Rasch CR, et al. Impact of rectal cancer target volume consensus atlas implementation in the cooperative group setting: Preliminary results from a prospective randomized double-blind pilot study 2010, Paper presented at: 2010 Gastrointestinal Cancers Symposium.
42. Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009, 74(3):824-830. 10.1016/j.ijrobp.2008.08.070, 2709288, 19117696.
43. Taylor N, Crane C, Skibber J, et al. Elective groin irradiation is not indicated for patients with adenocarcinoma of the rectum extending to the anal canal. Int J Radiat Oncol Biol Phys 2001, 51(3):741-747. 10.1016/S0360-3016(01)01687-X, 11597817.
44. Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys 2002, 54(2):386-396. 10.1016/S0360-3016(02)02945-0, 12243812.
45. Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004, 22(10):1785-1796. 10.1200/JCO.2004.08.173, 15067027.
46. Guillem JG, Diaz-Gonzalez JA, Minsky BD, et al. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol 2008, 26(3):368-373. 10.1200/JCO.2007.13.5434, 18202411.
47. Garcia-Aguilar J, Shi Q, Thomas CR, et al. A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. Ann Surg Oncol 2012, 19(2):384-391. 10.1245/s10434-011-1933-7, 21755378.
48. Habr-Gama A, Perez RO, Proscurshim I, et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg 2006, 10(10):1319-1328. discussion 1328-1319, 10.1016/j.gassur.2006.09.005, 17175450.